Evidence map›Paper›PMID 42688305›Full record

Trial reportFrontiers in immunology2026

A phase III clinical trial on the immunogenicity of a tetanus vaccine, adsorbed in individuals aged 18 years and above in China.

Qiuyue Mu, Zhe Li, Xiaolong Li, Tian Feng, Yajun Tan, Xue Wang, Feiyu Wang, Yuanxue Gao, Xiuwen Sui, Peng Wan and 8 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06120751 (A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06120751 phase3completednot on this map

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

TypeinterventionalSponsorCanSino Biologics Inc.Ran2024 to 2024Enrolled1,000ConditionsTetanusArmsTTVA, TT
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Qiuyue Mu *Guizhou Province Centers for Disease Control and Prevention, Guiyang, China.
Zhe Li *National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, Beijing, China.
Xiaolong Li *CanSino Biologics Inc., Tianjin, China.
Tian FengGuizhou Province Centers for Disease Control and Prevention, Guiyang, China.
Yajun TanNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, Beijing, China.
Xue WangCanSino Biologics Inc., Tianjin, China.
Feiyu WangCanSino Biologics Inc., Tianjin, China.
Yuanxue GaoGuizhou Province Centers for Disease Control and Prevention, Guiyang, China.
Xiuwen SuiCanSino Biologics Inc., Tianjin, China.
Peng WanCanSino Biologics Inc., Tianjin, China.
Guoxia DongNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, Beijing, China.
Shunda ZhangCanSino Biologics Inc., Tianjin, China.
Bingzhuo ShiCanSino Biologics Inc., Tianjin, China.
Jinbo GouCanSino Biologics Inc., Tianjin, China.
Yuhang JiaoGuizhou Province Centers for Disease Control and Prevention, Guiyang, China.
Haitao HuangCanSino Biologics Inc., Tianjin, China.
Liyong YuanNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, Beijing, China.
Ruizhi ZhangGuizhou Province Centers for Disease Control and Prevention, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the immunogenicity of a tetanus vaccine, adsorbed (TTVA) in people aged 18 years and above. Methods: A randomized, double-blinded, and positive controlled clinical trial was conducted in Bijie, Guizhou Province, China. Participants aged 18 years and above were recruited and randomly assigned 1:1 to receive the experimental (TTVA) or control tetanus vaccine, adsorbed (TT) vaccine. Serum samples were collected from all participants before vaccination, 30 days after vaccination, and 6 months after vaccination in the first 240 participants to detect tetanus toxoid IgG antibody levels. Results: At 30 days after vaccination, the geometric mean concentration (GMC) of antibodies in the experimental group and the control group were 3.205 and 2.387 ( Conclusion: TTVA vaccine has good immunogenicity in people aged 18 years and above. Clinical trial registration: https://clinicaltrials.gov, identifier NCT06120751.

Indexed as

Immunogenicity, VaccineTetanusTetanus ToxoidAdolescentAdultAgedAntibodies, BacterialChinaDouble-Blind MethodFemaleHumansImmunoglobulin GMaleMiddle AgedVaccinationYoung AdultAntibodies, BacterialImmunoglobulin GTetanus Toxoidadsorbedimmunogenicityimmunogenicity persistencephase III clinical trialpositive control designtetanus vaccine

Identifiers

PMID42688305
PMCPMC13533956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.